Business Wire

SwitchDin’s Technology Selected for World-First Project to Increase Solar Hosting Capacity for Electricity Distribution Networks

1.10.2020 23:00:00 EEST | Business Wire | Press release

Share

SwitchDin, an Australian energy management software company, has been retained by distribution networks, SA Power Networks and AusNet Services, to provide a global-first solution that will allow networks to create flexible solar export limits to accommodate the growth of rooftop solar photovoltaic (PV) systems that are connected to the grid.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005065/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SwitchDin CEO Dr Andrew Mears with SwitchDin Droplet controller (Photo: Business Wire)

The installation of PV systems is growing at a rate of more than 200,000 each year in Australia’s National Electricity Market (NEM), and distribution networks are reaching the limit of their ability to host rooftop solar in some areas. This flexible export capability will allow SA Power Networks and AusNet Services to offer an alternative to the strict export limits currently required to address these challenges, increasing the penetration of renewable energy, creating more value for customers and improving the security of the grid.

The project is backed with over A$2 million in direct funding by the Australian Renewable Energy Agency (ARENA), with additional financial contributions from SwitchDin, SA Power Networks, AusNet Services and inverter manufacturers involved in the program. A 12 month trial involving a group of 600 customers in South Australia and Victoria will test the viability of this approach so it can be offered as a standard service to solar customers in future.

SwitchDin will lead in the project’s integration architecture design and will provide the core software platform for SA Power Networks and AusNet Services to support the flexible export functionality, based on the international ‘Smart Grid’ standard IEEE 2030.5. The flexible export capability will be enabled for solar inverters through connection to SwitchDin’s Droplet controller devices, or by connection via the internet into SwitchDin’s IEEE 2030.5 utility server platform.

Dr Andrew Mears, CEO of SwitchDin said, “SwitchDin is proud to be developing the technology backbone of the Flexible Exports project in South Australia and Victoria. This is another example of how we are working with Australia’s most progressive network service companies and the world’s best inverter manufacturers to bring smart software solutions to maximise the value of distributed energy resources such as rooftop solar for consumers and energy service providers alike.

“SwitchDin’s goal is to deliver smarter and cheaper clean energy services on the grid for the benefit of everyone. In the Australian market, the pressing issue is high penetration of rooftop solar, but our platform can also support battery storage and key loads such as heat pumps and electric vehicles as part of a complete ‘energy flexibility’ toolkit.”

“We want more solar, not less,” said Paul Roberts, Manager Corporate Affairs at SA Power Networks. “SA Power Networks is passionate about supporting South Australia’s energy transition and we have a number of initiatives underway that have the potential to double the amount of renewable energy the SA electricity distribution network can accommodate over the next five years.”

“By working with SwitchDin and the other project partners, SA Power Networks and AusNet Services are paving the way for distribution networks to continue to host the rooftop solar systems being installed by customers whilst reducing the need for major investment in network upgrades. This is a winning value proposition for energy distribution network companies globally who are grappling with how to meet customers’ expectations to be more energy independent.”

Building on past successes

SwitchDin solves one of the great roadblocks faced by today’s electricity system, the management at-scale of many distributed energy resources such as small-scale solar, batteries and loads like electric vehicles and HVAC systems. The company’s technology bridges the gap between traditional energy utilities, manufacturers and energy end-users by bringing rich data, intelligence and real-time fleet control capabilities to these assets.

In addition to the Flexible Exports project, SwitchDin is actively working with utilities and equipment manufacturers from around the world to build the grid of the future. The company connects and manages distributed assets with its Droplet controllers and smart software and provides cloud-level orchestration using its StormCloud management platform. SwitchDin can connect with upstream third party and utility distribution management systems or energy trading tools to ensure a smooth transition to clean and affordable electricity.

Note to Editor: Hi-res images can be downloaded here.

About SwitchDin:

SwitchDin is an energy technology company that plays a critical role in the energy transition by making distributed energy resources (DERs) such as solar PV and battery storage smart, visible and controllable. SwitchDin is paving the way for the integration of more renewables into the world’s energy system. Working in collaboration with energy utilities, equipment manufacturers, technology providers and facility managers, SwitchDin’s virtual power plant and microgrid management platform delivers new partnerships that unlock value for everyone connected to the grid. www.switchdin.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

James Martin
+61 478 587 396
james.martin@switchdin.com

Gabriel Wong / Olivia Smith for SwitchDin
+61 432 177 005 / +61 402 044 811
gabriel@positivegood.com.au / olivia@positivegood.com.au

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye